New indication for IMFINZI®

IMFINZI (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) was recently approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Read the press release here.

View indications and prescribing information.